EHA 2023 | COMMANDS study: efficacy & safety results and biomarker analysis
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, shares the results of the COMMANDS study (NCT03682536) investigating the efficacy and safety of luspatercept versus epoetin alfa for the treatment of ESA-naïve low-risk myelodysplastic syndromes (MDS)-associated transfusion-dependent anemia. The study showed the superiority of luspatercept over epoetin alfa in terms of transfusion independence, hemoglobin increase, and durability of response. In addition, data from translational studies showed that the pathways that were activated or downregulated by luspatercept and epoietin alfa and that correlated with clinical response were different. Prof. Platzbecker explains that luspatercept appears to be selectively differentiating late-stage progenitor cells whilst epoetin alfa is targeting early progenitor cells. This complementary action has led to studies investigating the combination of luspatercept and epoetin alfa. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Grant support, paid to GWT-TUD, from Amgen; lecture fees and grant support, paid to the University of Leipzig, from Amgen; fees for serving on a steering committee, consulting fees, and travel support from Bristol Myers Squibb; grant support, paid to GWT-TUD, from Janssen Biotech; grant support, paid to University Dresden, from Merck and Novartis; lecture and consulting fees from Novartis; and consulting fees from AbbVie, Curis, and Geron.
